Introduces the NGX 124 qPCR Molecular Diagnostic Platform
Low-Cost, High Throughput, Fully Open
Fast MDx is a registered Social Enterprise which provides Molecular Diagnostic (MDx) testing that will benefit society and dramatically less impact the environment
Almost half the world’s population has little or no access to diagnostics, Fast MDx aims to provide affordable MDx to all peoples of the world, regardless of income or location
Low Cost Testing...
No CapEx as the Fast MDx platform is lent as part of the low cost test contract
No packaging cost
No transportation costs
No Biosecure lab overheads
Single technician operation
Ultra-Fast Fully Automated Results...
Faster Results
Earlier treatment
Better outcomes
Reduced spread of infectious disease
High-Throughput Testing...
1000+ Patient
test results per 8 hour shift
up to 5 times more efficient than manual test processing
Lowest Carbon Footprint...
Reduced transportation
and packaging
The Ultra-Fast
NGx2 4-Channel qPCR
thermal cycle minimizes
electrical use
Fully automated optimized sample processing reduces handling errors and the need to retest
Low Cost Testing
Ultra-Fast Fully Automated Results
No CapEx as the Fast MDx platform is lent as part of the low cost test contract
No packaging cost
No transportation costs
No Biosecure lab overheads
Single technician operation
Faster Results
Earlier treatment
Better outcomes
Reduced spread of infectious disease
High- Throughput Testing
Lowest Carbon Footprint
1000+ Patient
test results per 8 hour shift
up to 5 times more efficient than manual test processing
Reduced transportation and packaging
The Ultra-Fast NGx2 4-Channel qPCR thermal cycle minimizes electrical use
Fully automated optimized sample processing reduces handling errors and the need to retest
PRECISION
TESTING
HIGH-
THROUGHPUT
LOW COST
GREENER
TESTING
ULTRA-FAST
RESULTS
Richard Lewis, Fast MDx CEO, spoke at Lab Innovations at the NEC on 30 October 2024 as a case study for Festo automation. Read the full transcript...
Fast MDx Ltd, a London-based social enterprise, believes that their innovative molecular diagnostics test platform, the NGX 124, will revolutionize the early detection and quarantining of highly infectious diseases to prevent the spread of pandemics in the future.
Fast MDx was delighted to read an item in Genome Web covering our system obtaining the CE-IVDR mark for a fully automated, high-throughput open molecular diagnostic test system called NGX 124.
An ‘open’ Molecular Diagnostic system which perfectly describes the Fast MDx platform, would be a “game-changer” in Low- and Middle-Income Countries (LMIC), according to a recent Belgium academic paper published in Expert Review of Molecular Diagnostics .
